SCHEMBL12043125

SCHEMBL12043125

CCCc1ccc2nc(N3CCN(C(=S)Nc4ccccc4F)CC3)c(C#N)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 11/20 0.51
▸ KDM4E B2RXH2 10/20 0.51
▸ TSHR P16473 4/20 0.51
▸ CASP1 P29466 4/20 0.51
▸ CFTR P13569 1/20 0.49
▸ KMT2A Q03164 5/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ LMNA P02545 4/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ CASP7 P55210 3/20 0.48
▸ ATM Q13315 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ MAPT P10636 3/20 0.42
▸ GAA P10253 1/20 0.42
▸ HPGD P15428 2/20 0.42
▸ PKM P14618 1/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14073368 0.88 KDM4E (0.64) ALDH1A1KDM4ETSHRCASP1CFTR
SCHEMBL12043114 0.86 KDM4E (0.64) ALDH1A1KDM4ETSHRCASP1CFTR
SCHEMBL1445522 0.84 KDM4E (0.69) ALDH1A1KDM4ETSHRCASP1CFTR
SCHEMBL12043192 0.81 ALDH1A1 (0.52) ALDH1A1KDM4ETSHRCASP1CFTR
SCHEMBL14073363 0.78 KDM4E (0.61) ALDH1A1KDM4ETSHRCASP1KMT2A
SCHEMBL14073362 0.76 KDM4E (0.70) ALDH1A1KDM4ETSHRCASP1CFTR
SCHEMBL16940596 0.75 KDM4E (0.62) ALDH1A1KDM4ETSHRCASP1CFTR
SCHEMBL16940595 0.74 KDM4E (0.74) ALDH1A1KDM4ETSHRCASP1CFTR
SCHEMBL2525573 0.74 KDM4E (0.84) ALDH1A1KDM4ETSHRCASP1CFTR
SCHEMBL14601359 0.73 PKM (0.51) ALDH1A1KDM4ETSHRCASP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9539261-B2 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration NEURONASCENT, INC. (US) 2017-01-10 — — US disclosed
US-20150209371-A1 Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration NEURONASCENT, INC. 2015-07-30 — — US disclosed
US-8999972-B2 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration NEURONASCENT, INC. (US) 2015-04-07 — — US disclosed
US-20110319391-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION NEURONASCENT, INC. 2011-12-29 — — US disclosed
US-8039462-B2 Alzheimer's disease, stroke, traumatic brain injury, and depression, neurodegenerative diseases; antidepressants; a phenyl thiourea or urea derivatives; promote cell proliferation of stem or progenitor cells NEURONASCENT, INC. (US) 2011-10-18 — — US disclosed
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration NEURONASCENT, INC. (US) 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319391-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION DCX, BDNF, GAP43 ALDH1A1 874/4885KDM4E 3732/4885TSHR 3333/4885
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration DCX, BDNF, GAP43 ALDH1A1 1544/4885KDM4E 4443/4885TSHR 2962/4885
US-20150209371-A1 Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration DCX, BDNF, GAP43 ALDH1A1 874/4885KDM4E 3732/4885TSHR 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback